secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2023-04-14T23:59:59+00:00
Accession:  0001437749-23-010220
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SAB Biotherapeutics receives FDA Fast Track Designation for SAB-176 influenza immunotherapy for high-risk patients
--------------------------------------------------------------------------------

- Fast Track Designation granted for SAB-176, an investigational therapeutic for Type A and B influenza in high-risk patients, including those with antiviral-resistant strains.
- FDA aligned on Phase 2b trial design evaluating safety and efficacy in high-risk patients; manufacturing approach also aligned.
- SAB-176 is a fully-human polyclonal IgG antibody produced without human donors via the DiversitAb platform.
- Phase 2a data showed broad cross-protection against multiple influenza strains, including non-targeted strains.
- The designation enables frequent FDA interactions, priority review, and rolling review eligibility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000143774923010220/0001437749-23-010220-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000143774923010220/sabs20230413_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-010220

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer